DDInter875 DDInter1806
Human papillomavirus type 11 L1 capsid protein antigen is contained in Gardasil, or a recombinant Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) vaccine for intramuscular injection. It is an immunization for young men and women 9-26 years of age for the prevention of diseases caused by Human Papillomavirus (HPV) types 6, 11, 16 and 18. The vaccine is prepared from the purified virus-like particles (VLPs) of the major capsid (L1) protein of HPV Types 6, 11, 16, and 18, which are produced by separate fermentations in recombinant *Saccharomyces cerevisiae* and self-assembled into VLPs.
Tildrakizumab is a high-affinity, humanized, IgG1 κ antibody targeting interleukin 23 p19 that shows promise in the evolution of treatment strategy in chronic plaque psoriasis . The Food and Drug Administration (FDA) approved ILUMYA (tildrakizumab-asmn) for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy in March 2018. The approved recommended dosage of ILUMYA is a subcutaneous injection of 100 mg at Weeks 0, 4, and every 12 weeks thereafter . A study was performed on the pharmacokinetics of this drug on various ethnicities. The pharmacokinetics of tildrakizumab were similar in Japanese, Caucasian, and Chinese subjects .
Tildrakizumab {u} may cause a minor interaction that can limit clinical effects when taken with {v} Zinc sulfate
Tildrakizumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Alefacept
Tildrakizumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Human adenovirus e serotype 4 strain cl-68578 antigen
Tildrakizumab {u} may lead to a major life threatening interaction when taken with {v} Bacillus calmette-guerin substrain tice live antigen
Tildrakizumab {u} may lead to a major life threatening interaction when taken with {v} Smallpox (Vaccinia) Vaccine, Live
Tildrakizumab may cause a minor interaction that can limit clinical effects when taken with Zinc sulfate
Tildrakizumab may cause a moderate interaction that could exacerbate diseases when taken with Alefacept
Tildrakizumab may cause a moderate interaction that could exacerbate diseases when taken with Human adenovirus e serotype 4 strain cl-68578 antigen
Tildrakizumab may lead to a major life threatening interaction when taken with Bacillus calmette-guerin substrain tice live antigen
Tildrakizumab may lead to a major life threatening interaction when taken with Smallpox (Vaccinia) Vaccine, Live